Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials

M. Clarke, A. S. Coates, S. C. Darby, C. Davies, R. D. Gelber, Jon Godwin, A. Goldhirsch, R. Gray

    Research output: Contribution to journalArticle

    Abstract

    The long-term effects of adjuvant polychemotherapy regimens in oestrogen-receptor-poor (ER-poor) breast cancer, and the extent to which these effects are modified by age or tamoxifen use, can be assessed by an updated meta-analysis of individual patient data from randomised trials. Collaborative meta-analyses of individual patient data for about 6000 women with ER-poor breast cancer in 46 trials of polychemotherapy versus not (non-taxane-based polychemotherapy, typically about six cycles; trial start dates 1975–96, median 1984) and about 14 000 women with ER-poor breast cancer in 50 trials of tamoxifen versus not (some trials in the presence and some in the absence of polychemotherapy; trial start dates 1972–93, median 1982).

    Original languageEnglish
    Pages (from-to)29-40
    Number of pages12
    JournalLancet
    Volume371
    Issue number9606
    DOIs
    Publication statusPublished - 1 Jan 2008

    Keywords

    • breast cancer
    • oestrogen receptor
    • adjuvant therapy
    • clinical trials
    • chemotherapy

    Fingerprint Dive into the research topics of 'Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials'. Together they form a unique fingerprint.

  • Cite this

    Clarke, M., Coates, A. S., Darby, S. C., Davies, C., Gelber, R. D., Godwin, J., Goldhirsch, A., & Gray, R. (2008). Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet, 371(9606), 29-40. https://doi.org/10.1016/S0140-6736(08)60069-0